



Change of Company Secretary

11 December 2024

LTR Pharma Limited (ASX:LTP) ("**LTR Pharma**", "the **Company**"), a company focused on improving men's health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction, SPONTAN®, advises, in accordance with ASX Listing Rule 3.16.1, that Ms Shelby Coleman of Automic Group will be appointed as Company Secretary, effective immediately. For the purposes of ASX Listing Rule 12.6, Ms Coleman will be the primary person responsible for communications with ASX in relation to Listing Rule matters.

Ms Belinda Cleminson has notified the Board of her resignation as Company Secretary, effective immediately. Ms Cleminson will step down as Company Secretary following her resignation from Automic Group, the Company's corporate secretarial services provider. The Company thanks Ms Cleminson for her support of the Board during her time with the Company.

– ENDS –

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma's lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information, please contact:

Haley Chartres
Media Relations
haley@hck.digital

Peter McLennan
Investor Relations
investors@ltrpharma.com